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Abstract Neoadjuvant chemotherapy has the advantage
of converting unresectable breast tumors to resectable tu-
mors and allowing more conservative surgery in some
mastectomy candidates. Chemotherapy agents, including
taxanes, which are recommended in the adjuvant setting,
are also considered in the neoadjuvant setting. Here, we
review studies of nab-paclitaxel as a neoadjuvant treatment
for patients with breast cancer. PubMed and conference or
congress proceedings were searched for clinical studies of
nab-paclitaxel in the neoadjuvant treatment of breast can-
cer. We also searched ClinicalTrials.gov for ongoing trials
of nab-paclitaxel as a neoadjuvant agent in breast cancer.
Twenty studies of nab-paclitaxel in the neoadjuvant setting
were identified. In addition to reviewing key efficacy and
safety data, we discuss how each trial assessed response,
focusing on pathologic complete response and residual
cancer burden scoring. Safety profiles are also reviewed.
nab-Paclitaxel demonstrated antitumor activity and an
acceptable safety profile in the neoadjuvant treatment of
breast cancer. Ongoing and future trials will further eval-
uate preoperative nab-paclitaxel in breast cancer, including
in combination with many novel immunological targeted
therapies.
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Background
Introduction to neoadjuvant therapy
Breast cancer remains one of the most commonly diag-
nosed cancers in the United States, representing 29 % of
annual cancer diagnoses in women [1]. More than 200,000
new cases of invasive breast cancer, with approximately
40,000 related deaths, were expected in 2015 [1]. The
5-year survival rate for all stages of breast cancer combined
is 89 % [1]. However, patients with localized breast cancer
have a higher 5-year survival rate of 99 % compared with
those with regional disease in the axillary lymph nodes,
which confers a 5-year survival rate of 85 % [1]. Meta-
static dissemination further reduces 5-year survival rates to
25 % [1].
Surgery with the goal of removing the primary tumor
and achieving negative tumor margins is the primary
therapeutic approach for minimizing risk of recurrence and
increasing survival of patients with early-stage breast
cancer. Chemotherapy before surgery, or neoadjuvant
chemotherapy, helps convert large, unresectable tumors to
resectable tumors [2, 3]. In addition, neoadjuvant therapies
can shrink operable tumors, allowing breast-conserving
surgery to be performed instead of mastectomy [2, 3].
Regional disease may also be decreased with the use of
sentinel lymph node biopsy, potentially reducing the need
for axillary lymph node dissection [4].
In addition to treatment benefits, neoadjuvant studies
provide valuable tissue samples for biomarker evaluation.
Because loco-regional responses to neoadjuvant therapies
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correlate with long-term outcomes, neoadjuvant therapies
also offer unique opportunities for early prediction of
responses and individualization of treatment.
Using pathologic complete response (pCR)
and residual cancer burden (RCB) as endpoints
in neoadjuvant studies
The US Food and Drug Administration (FDA) supports
pCR as an endpoint for evaluating new neoadjuvant agents
for high-risk, early-stage breast cancer [5, 6]. pCR is
defined by the FDA as the ‘‘absence of residual invasive
cancer in the complete resected breast specimen and all
sampled regional lymph nodes following completion of
neoadjuvant systemic therapy (i.e., ypT0/Tis ypN0 in the
current AJCC staging system)’’ or ‘‘absence of the residual
invasive and in situ cancers in the complete resected breast
specimen and all sampled regional lymph nodes following
completion of neoadjuvant systemic therapy (i.e.,
ypT0ypN0)’’ [6]. In a large FDA-led meta-analysis, pCR
defined as ypT0/isypN0 or ypT0ypN0 was more closely
associated with improved survival compared with ypT0/is
(defined as absence of invasive cancer in the breast irre-
spective of ductal carcinoma in situ or nodal involvement)
[3, 5]. It is important to note that, according to the FDA,
‘‘high risk’’ specifically refers to ‘‘patients with early-stage
breast cancer who have a high risk of distant disease
recurrence and death despite use of optimal modern local
and systemic adjuvant therapy’’ [6]. Inclusion of patients
with low-grade, hormone receptor (HR)-positive tumors in
neoadjuvant breast cancer trials using pCR as an endpoint
is not recommended by the FDA; these patients generally
have better long-term outcomes compared with patients
with high-risk disease.
RCB also measures response to neoadjuvant agents [7].
RCB was initially devised to address the oversimplified
dichotomized pCR data and is derived from the dimensions
of the primary tumor, cellularity of the tumor bed, and
axillary node burden. Although RCB is not routinely
assessed in clinical trials, this measurement was used in
some of the studies reviewed here.
Chemotherapy in the neoadjuvant setting
Neoadjuvant versus adjuvant treatment with doxorubicin
and cyclophosphamide (AC) was first compared in opera-
ble breast cancer in NSABP B-18 [8]. No significant dif-
ferences in overall survival (OS; 55 % for both groups;
P = 0.90) or disease-free survival (DFS; 42 vs 39 %;
P = 0.27) were found after 16 years of follow-up. How-
ever, neoadjuvant AC reduced node-positive disease, with
a significantly increased percentage of negative axillary
nodes (58 vs 42 %; P\ 0.0001) and increased frequency
of breast-conserving surgery (68 vs 60 %; P = 0.001) [8].
EORTC trial 10902 also found no differences in 10-year
OS (64 vs 66 %; hazard ratio [HR] = 1.09; 95 % CI
0.83–1.42; P = 0.54) or DFS (48 vs 50 %; HR = 1.12;
95 % CI 0.90–1.39; P = 0.30) after preoperative vs post-
operative chemotherapy (fluorouracil, epirubicin, and
cyclophosphamide [FEC]) [9]. However, as reported by the
phase III European Cooperative Trial in Operable Breast
Cancer (ECTO), neoadjuvant vs adjuvant paclitaxelplus
doxorubicin, followed by cyclophosphamide, methotrex-
ate, and fluorouracil (AT ? CMF) significantly increased
the incidence of lumpectomy (63 vs 34 %; P\ 0.001)
despite no change in OS (HR = 1.10; P = 0.60) [10].
pCR was significantly correlated with DFS in the
NSABP B-18 trial (HR = 0.47; P\ 0.0001) or OS
(HR = 0.32; P\ 0.0001) [8], suggesting that pCR after
neoadjuvant treatment may predict favorable long-term
outcome. A meta-analysis conducted by the Collaborative
Trials in Neoadjuvant Breast Cancer (CTNeoBC), which
included approximately 12,000 patients in 12 randomized
trials, confirmed better long-term outcomes in patients who
achieved pCR (HR = 0.36; 95 % CI 0.31–0.42) [3]. In
addition, the TECHNO trial of neoadjuvant trastuzumab
plus chemotherapy for human epidermal growth factor
receptor 2 (HER2)-positive (?) breast cancer showed a
correlation between pCR and improved DFS (HR = 2.5;
95 % CI 1.2–5.1; P = 0.013) [11].
Role of neoadjuvant paclitaxel in breast cancer
Multiple clinical trials support paclitaxel in the neoadju-
vant treatment of breast cancer. ECTO established an in-
breast pCR of 23 % and breast-plus-node pCR of 20 %
after neoadjuvant AT followed by CMF [12]. The NOAH
trial showed similar results, with an in-breast pCR of 17 %
and breast-plus-node pCR of 16 % in HER2-negative
patients treated with neoadjuvant AT followed by pacli-
taxel and CMF [13]. In patients with HER2?positive dis-
ease treated with neoadjuvant chemotherapy plus
neoadjuvant and adjuvant trastuzumab, pCR rates were
43 % in breast and 38 % in breast-plus axilla [13].
SWOG 0012 compared 21-day AC followed by pacli-
taxel versus weekly AC with granulocyte colony-stimu-
lating factor (G-CSF) support followed by paclitaxel [14].
Although pCR was slightly higher after weekly AC plus
paclitaxel (24.3 vs 20.7 %; P = 0.45), a significantly
higher pCR was achieved in patients with stage IIIB dis-
ease who received weekly AC versus 21-day AC (25.8 vs
9.3 %; P = 0.0057). Subsequently, phase III Neo-tAnGo
found that paclitaxel followed by anthracyclines signifi-
cantly improved pCR compared with anthracyclines fol-
lowed by paclitaxel (20 vs 15 %; P = 0.03) [15].
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CALGB 40603 evaluated neoadjuvant weekly paclitaxel
followed by dose-dense AC ± bevacizumab and/or car-
boplatin for triple-negative breast cancer (TNBC) [16].
Carboplatin significantly increased breast pCR (60 vs
46 %; P = 0.0018) and breast-plus-axilla pCR (54 vs
41 %; P = 0.0029), whereas bevacizumab increased only
breast pCR (59 vs 48 %; P = 0.0089).
Neoadjuvant lapatinib plus trastuzumab followed by
neoadjuvant lapatinib plus trastuzumab plus paclitaxel
significantly improved pCR vs neoadjuvant trastuzumab
alone followed by neoadjuvant trastuzumab plus paclitaxel
(51.3 vs 29.5 %; P = 0.0001) in patients with HER2?
breast cancer in the NeoALTTO study [17]. Similarly,
NSABP B-41 reported higher pCR when neoadjuvant AC
followed by trastuzumab plus lapatinib plus paclitaxel was
compared with AC followed by trastuzumab plus paclitaxel
(62 vs 52.5 %; P = 0.095) [18]. CALGB 40601 also
demonstrated numerically increased pCR after weekly
paclitaxel plus trastuzumab plus lapatinib versus weekly
paclitaxel plus trastuzumab (51 vs 40 %; P = 0.11) [19].
These trials collectively support the efficacy of neoad-
juvant paclitaxel in all subtypes of breast cancer. As a
result, many National Comprehensive Cancer Network-
preferred neoadjuvant regimens now include taxanes [20].
Development of nab-paclitaxel
Paclitaxel is formulated with Kolliphor EL (formerly Cre-
mophor EL), which can elicit hypersensitivity reactions and
peripheral neuropathy [21]. Nanoparticle albumin-bound
paclitaxel (nab-paclitaxel, Celgene Corporation, Summit,
NJ) minimizes these toxicities and obviates prophylactic
antihistamine and steroid treatment [21, 22]. Compared with
paclitaxel, nab-paclitaxel yields a 10-fold higher mean
maximal concentration of free paclitaxel [23]. In addition,
nab-paclitaxel is transportedmore rapidly across endothelial
cell layers and exhibits greater tissue penetration and slower
elimination of paclitaxel [24, 25]. According to preclinical
models, increased intratumoral delivery and retention result
in 33 % higher intratumoral drug concentrations [24].
A significantly improved overall response rate (ORR) (33
vs 19 %; P = 0.001) and time to tumor progression (23.0 vs
16.9 weeks; HR= 0.75; P = 0.006) were reported for nab-
paclitaxel in a phase III trial of nab-paclitaxel (260 mg/m2
every 3 weeks [q3w]) vs paclitaxel (175 mg/m2 q3w) in
metastatic breast cancer (MBC) [26]. nab-Paclitaxel was
associated with a lower incidence of grade 4 neutropenia (9
vs 22 %;P\ 0.001) and higher incidence of grade 3 sensory
neuropathy (10 vs 2 %; P\ 0.001). In a subsequent phase II
trial of first-line nab-paclitaxel vs docetaxel for MBC, nab-
paclitaxel 150 mg/m2 the first 3 of 4 weeks (qw 3/4) sig-
nificantly prolonged PFS by independent (12.9 vs
7.5 months; P = 0.0065) and investigator (14.6 vs
7.8 months; P = 0.012) review vs docetaxel [22]. In addi-
tion, nab-paclitaxel improved ORR, although the difference
was not significant. Grade 3 fatigue and grade 4 neutropenia
were lower with nab-paclitaxel, whereas the incidence of
grade 3/4 sensory neuropathy was similar. These trials sup-
port the overall efficacy and safety of nab-paclitaxel inMBC.
Methods
The search terms ‘‘nab-paclitaxel’’ or ‘‘nanoparticle pacli-
taxel’’ and ‘‘breast cancer’’ and ‘‘neoadjuvant’’ and ‘‘clin-
ical trial’’ were applied to retrieve publications from
PubMed and presentations from conferences and con-
gresses, including American Society of Cancer Oncology
annual meetings, Breast Cancer Symposium, and the San
Antonio Breast Cancer Symposium. Results were evalu-
ated for study design and key efficacy and safety data with
a focus on TNBC.
Results
Twenty studies of neoadjuvant nab-paclitaxel in breast
cancer were retrieved (Table 1). Most reported the results
of phase II trials. Disease subtype varied among studies, as
did treatment dose and schedule. Study design, including
doses and sequencing of agents, and key results are sum-
marized (Table 1). In addition, key safety data are provided
(Table 2).
Unselected disease
nab-Paclitaxel (260 mg/m2 q3w) plus capecitabine was
evaluated for previously untreated locally advanced breast
cancer (LABC) in a phase II study (N = 14) [27]. The
study was terminated early due to a low response rate.
Grade 3/4 toxicities included hand-foot syndrome, neu-
tropenia or neutropenic fever, syncope, and hypertension.
In another phase II trial, gemcitabine and epirubicin
were combined with neoadjuvant nab-paclitaxel (175 mg/
m2 every 2 weeks [q2w]) for LABC (N = 123) [28].
Pegfilgrastim was also administered. pCR occurred in
20 % of patients, and 3-year PFS and OS were 48 and
86 %, respectively. Among 44 patients with TNBC, 12
(27 %) had pCR. The most common grade 3/4 toxicity,
occurring in 11 % of patients, was neutropenia. Grade 3
sensory neuropathy occurred in 3 (2 %) patients, with no
grade 4 sensory neuropathy. Non-hematologic toxicities
were uncommon.
nab-Paclitaxel (100 mg/m2 once weekly [qw]) followed
by FEC was evaluated for previously untreated LABC in a
phase II trial (N = 66) [29]. Patients with HER2? disease
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also received trastuzumab. An in-breast pCR of 29 % and
breast-plus-node pCR of 26 % were reported. Analysis by
molecular subtype showed pCR in 28 % of TNBC, 70 % of
HR-/HER2?, and 44 % of HR?/HER2? patients. PFS and
OS were 81 and 95 %, respectively, for the intent-to-treat
(ITT) population. The regimen was tolerable, with no grade
4 toxicities due to nab-paclitaxel treatment. Grade 3/4
febrile neutropenia due to FEC occurred in 7 % of patients.
nab-Paclitaxel (125 mg/m2 qw; n = 30) and paclitaxel
(80 mg/m2 qw; n = 90) were recently compared in com-
bination with carboplatin in a phase II trial for LABC [30].
Trastuzumab was added for HER2? disease. pCR rates
were similar (26.7 vs 25.6 % with nab-paclitaxel vs
paclitaxel, respectively; P = 0.904), and no differences
were found with trastuzumab (43.6 vs 39.6 %; P = 0.769).
One of two patients with TNBC achieved pCR with nab-
paclitaxel. Interestingly, nab-paclitaxel showed benefit in
patients with stage II disease, with a pCR of 36.8 versus
15.8 % with paclitaxel (P = 0.051). No grade 3/4 periph-
eral neurotoxicity was reported in either arm. However,
grade 4 neutropenia increased with nab-paclitaxel (56.7 vs
21.1 %; P\ 0.001).
nab-Paclitaxel with HER2-targeted therapies
Several studies examined nab-paclitaxel for HER2-over-
expressing breast cancer. nab-Paclitaxel (260 mg/m2 q3w)
plus lapatinib was investigated in a phase I study for early-
stage, HER2? breast cancer (N = 30) [31]. A pCR of
17.9 % (95 % CI 3.7–32.1 %) was reported, with fatigue
and diarrhea being the most common grade 3 toxicities. No
grade 4 toxicities were reported.
A recent phase II study of preoperative nab-paclitaxel
(260 mg/m2 q2w) followed by vinorelbine plus trastuzumab
in HER2-overexpressing breast cancer (N = 27) reported a
pCR of 48 % [32]. Sub-analysis by HR status showed a pCR
of 18 % in patients with estrogen receptor (ER)?/proges-
terone receptor (PR)? disease and 69 % in patients with
ER-/PR- disease. Six patients had grade 2/3 neuropathy,
with no grade 4 neuropathy reported. Similarly, another
Table 2 Adverse events (all grade) by schedule in neoadjuvant studies of nab-paclitaxel
Trial nab-P schedule and dose Neutropenia (%) Peripheral neuropathy (%) Fatigue (%)
Veerapaneni [27] q3w 260 mg/m2 NR NR NR
Kaklamani [31] q3w 260 mg/m2 NR 0a 7a
Masumoto [71] q3w NR NR NR
Shimada [40] q3w 260 mg/m2 37.7 1.9 NR
Tanaka [33] q3w 260 mg/m2 36 84b 64
Yardley [28] q2w 175 mg/m2 11 2b 7
Zelnak [32] q2w 260 mg/m2 38 88 73
Robidoux [29] qw 100 mg/m2 3a 5a 6a
Sinclair [34] qw 100 mg/m2 75 0c 13
Sinclair [73] qw 100 mg/m2 71a 7a,c 7a
Nahleh [35] qw 100 mg/m2 NR NR NR
Untch [39] qw 125 mg/m2d 60.8a 10.4a 5a
Connolly [72] qw 100 mg/m2 NR NR NR
Huang [30] qw 125 mg/m2 100 43e NR
Mrozek [36] qw 3/4 100 mg/m2 58a NR NR
Yardley [52] qw 3/4 100 mg/m2 39a 0a NR
Khong [68] qw 2/3 100 mg/m2 NR NR NR
Li [69] NR NR NR NR
Snider [70] qw 3/4 100 mg/m2 78a NR 5
Martin [37] qw 3/4 150 mg/m2 16a 2.5a 3.7a
NR not reported, q3w every 3 weeks, qw once weekly, q2w every 2 weeks, qw 2/3 the first 2 of 3 weeks, qw 3/4 for the first 3 of 4 weeks
a Grade 3/4
b Reported as sensory neuropathy
c Reported as neurosensory
d Dose reduced from 150 mg/m2 qw (n = 229) to 125 mg/m2 qw (n = 377) after study amendment
e Reported as peripheral neurotoxicity
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phase II trial of neoadjuvant anthracycline followed by nab-
paclitaxel (260 mg/m2 q3w) plus trastuzumab reported
49 % pCR in the ITT group for operable HER2? breast
cancer (N = 46) [33]. A pCR of 71 %was achieved in cases
with ER- disease compared with 36 % in ER? disease.
Hematologic toxicities were the most common cause of
treatment delays or dose reductions, with one case of
peripheral neuropathy requiring dose reduction.
In general, compared with patients with HER2?/HR? dis-
ease, those with HR-/HER2? cancer had higher pCR rates.
Response rates to lapatinib plus nab-paclitaxel were low.
nab-Paclitaxel with bevacizumab
Neoadjuvant nab-paclitaxel plus bevacizumab has also
been evaluated as a potential treatment for breast cancer. In
a study of weekly nab-paclitaxel (100 mg/m2), carboplatin,
and bevacizumab with (n = 31) or without (n = 29) dose-
dense AC, pCR was 11 and 27 % in the ITT group and
TNBC subset, respectively [34]. Addition of dose-dense
AC increased pCR to 54 %, with a pCR of 81 % in the
TNBC subpopulation. Grade 3/4 toxicities included neu-
tropenia, thrombocytopenia, and anemia, with no grade 3/4
neurosensory toxicities.
Weekly neoadjuvant nab-paclitaxel (100 mg/m2) ± be-
vacizumab followed by dose-dense AC was evaluated for
HER2- LABC in phase II SWOG S0800 (N = 215) [35].
The overall pCR was 28 %, but a significantly higher pCR
was achieved with bevacizumab (36 vs 21 %; P = 0.021).
In HR? patients, the difference was not significant (be-
vacizumab vs no bevacizumab, 25 vs 18 %; P = 0.41).
However, HR- patients had significantly improved pCR
with bevacizumab (59 vs 28 %; P = 0.014). Grade 3/4
toxicities were common and not significantly different
between arms. In another phase II study, nab-paclitaxel
(100 mg/m2 qw 3/4), carboplatin, and bevacizumab
achieved a pCR of 21 % in the ITT group (N = 33), with a
pCR of 55 % in TNBC patients [36]. Neutropenia and
thrombocytopenia were the main toxicities.
These trials demonstrated efficacy of nab-paclitaxel
with bevacizumab in combination with carboplatin or dose-
dense AC for TNBC. However, hematologic toxicities
were common and should be monitored with this treatment
combination.
Recent trials
GEICAM (ITT N = 83; phase II) investigated neoadjuvant
nab-paclitaxel (150 mg/m2 qw 3/4) in HER2- breast
cancer and reported an ORR of 76.5 % [37]. RCB 0 ? I
was reported in 24.7 % of the treated population. In addi-
tion, 40 % of patients received breast-conserving surgery
after nab-paclitaxel. Ki-67[ 20 % and high stromal Cav1
correlated with low RCB (RCB 0 ? I), suggesting pre-
dictive roles for these markers. Grade 3/4 neutropenia
(16 %), leukopenia (3.7 %), fatigue (3.7 %), and neu-
ropathy (2.5 %) were the most common toxicities [38].
The phase III GeparSepto trial compared neoadjuvant
paclitaxel 80 mg/m2 qw (n = 600) vs nab-paclitaxel
(n = 606; dose reduced from 150 mg/m2 qw [n = 229] to
125 mg/m2 qw [n = 377] after study amendment) fol-
lowed by epirubicin and cyclophosphamide (EC) as part of
a neoadjuvant regimen for early-stage breast cancer [39].
Patients with HER2? disease were also treated with tras-
tuzumab plus pertuzumab. nab-Paclitaxel achieved signif-
icantly higher pCR vs paclitaxel, regardless of the pCR
definition (ypT0 ypN0, 38 vs 29 %, P = 0.00065; ypT0/is
ypN0, 43 vs 35 %, P = 0.004; ypT0/is ypN0/?, 49 vs
40 %, P = 0.002). The largest difference was in the TNBC
subgroup in which nab-paclitaxel achieved a pCR of 48
versus 26 % with paclitaxel (P\ 0.001). GeparSepto
originally used 150 mg/m2 weekly nab-paclitaxel, which
caused more peripheral neuropathy and more frequent
discontinuations than paclitaxel. Thus, after recruitment of
464 patients, the study protocol was amended to use
125 mg/m2 weekly nab-paclitaxel. For patients who were
randomized and started treatment before the amendment,
pCR occurred in 34 versus 23 % (P = 0.022) of the
patients in the nab-paclitaxel vs paclitaxel group. In
patients randomized on or after study amendment and who
started treatment, the pCR was 41 % in the nab-paclitaxel
group and 32 % in the paclitaxel group (P = 0.013). In a
subsequent study (N = 53), sequential nab-paclitaxel
(260 mg/m2 q3w) and EC achieved pCR in 3 (5.7 %) and
near-pCR in 7 (13.2 %) patients with stage II/III HER2-
breast cancer [40]. Grade 3 toxicities were rare and
included one case of peripheral neuropathy.
The randomized phase II Adjuvant Dynamic marker-
Adjusted Personalized Therapy (ADAPT) Triple Negative
trial of neoadjuvant nab-paclitaxel (125 mg/m2 qw 2/3)
plus carboplatin (N = 154) or gemcitabine (N = 182)
reported an overall pCR of 36 % with significant differ-
ences between arms (carboplatin, 45.9 % vs gemcitabine,
28.7 %; P\ 0.001) [41]. Early response (P\ 0.001) was
predictive of pCR regardless of treatment arm.
Toxicities
Most neoadjuvant nab-paclitaxel trials in breast cancer
demonstrated acceptable tolerability profiles (Table 2). A
few studies compared nab-paclitaxel vs paclitaxel in the
preoperative setting in patients with breast cancer. In the
GeparSepto study, nab-paclitaxel (150 or 125 mg/m2 qw)
followed by EC was associated with significantly improved
pCR rates and comparable grade 3/4 adverse events vs
paclitaxel followed by EC (neutropenia, 60.8 vs 61.7 %;
434 Breast Cancer Res Treat (2016) 156:427–440
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febrile neutropenia, 4.6 vs 4.0 %; fatigue, 5 vs 4 %) [39].
However, in patients treated with either nab-paclitaxel 150
or 125 mg/m2 qw, grade 3/4 peripheral sensory neuropathy
was significantly higher in the nab-paclitaxel arm vs
paclitaxel arm (10.4 vs 3 %, P\ 0.0001) [39]. In another
phase II study comparing nab-paclitaxel with carboplatin
vs paclitaxel with carboplatin as neoadjuvant therapy in
patients with LABC, the nab-paclitaxel arm had less grade
3/4 neutropenia (30 vs 52 %) and leukopenia (23 vs 35 %),
but slightly more thrombocytopenia (8 vs 0 %) and anemia
(5 vs 3 %) [30]. Overall, nab-paclitaxel appears to be a
promising neoadjuvant agent for breast cancer with an
acceptable safety profile; however, toxicities, including
peripheral neuropathy, should be monitored.
Discussion
Clinical trials of neoadjuvant nab-paclitaxel for breast
cancer have yielded highly encouraging results. Most trials
evaluated weekly or q3w nab-paclitaxel in combination
with anthracyclines, carboplatin, or cyclophosphamide, or
with targeted agents, such as bevacizumab or trastuzumab.
pCR rates ranged from 7 to 54 %, with the TNBC sub-
population demonstrating particularly strong responses,
ranging from 25.7 to 81 %. In general, pCR rates in TNBC
were significantly higher than those observed in other
breast cancer subtypes. Overall, neoadjuvant nab-paclitaxel
was safe, although hematologic toxicities were reported in
some studies. Results from the recent GeparSepto and
ADAPT TNBC trials were especially promising, with
significantly increased pCR rates after nab-paclitaxel fol-
lowed by EC, or carboplatin in patients with TNBC.
Additional ongoing trials will further examine the efficacy
of nab-paclitaxel-based regimens in TNBC. In addition, the
long-term effects of nab-paclitaxel need to be compared
with those of paclitaxel.
While data in the neoadjuvant setting are limited, some
clinical and economic data from model-based and retro-
spective analyses support the cost-effectiveness of nab-
paclitaxel in MBC [42, 43]. An economic analysis of a
phase II trial in MBC assessed the average cost of nab-
paclitaxel and docetaxel use from a United Kingdom
National Health Service perspective. Accounting for cost
components, including chemotherapy, drug delivery, and
hospitalization due to toxicity, the average costs of nab-
paclitaxel 100 and 300 mg/m2 q3w were comparable to the
cost of docetaxel 100 mg/m2 q3w (approximately £15,000
per patient for each nab-paclitaxel dose vs £12,000 per
patient for docetaxel) [42]. Furthermore, a meta-analysis of
randomized clinical trials in MBC found that nab-pacli-
taxel was associated with a lower incidence of grade 3/4
toxicities compared with paclitaxel and docetaxel and that
this translated to lower overall costs with respect to
managing these events [44].
Predictive biomarkers of response
Identification of predictive biomarkers continues to
advance individualized treatment of cancer patients. The
GeparSixto trial found a significant correlation between the
percentage of stromal tumor-infiltrating lymphocytes and
pCR after neoadjuvant carboplatin, anthracycline, and
taxane [45]. An unmet need exists in identifying patients
who are most likely to respond to nab-paclitaxel neoadju-
vant therapy by establishing biomarkers of response.
Secreted protein acidic and rich in cysteine (SPARC)
interacts with albumin and is localized in tumor stroma.
Thus, it was hypothesized that SPARC expression may
affect the antitumor activity of nab-paclitaxel [46–48].The
exact role of SPARC in tumor progression is unclear, as
some studies suggest a pro-tumorigenic and angiogenic
role, whereas others support an anti-tumorigenic role [48].
However, in an exploratory analysis from a large phase III
trial of patients with metastatic pancreatic cancer, SPARC
expression was neither predictive nor prognostic of OS
[49]. Future neoadjuvant nab-paclitaxel-based trials that
prospectively evaluate the predictive value of potential
molecular and biological markers are warranted.
Ongoing trials
Based on encouraging results with sequential neoadjuvant
nab-paclitaxel and FEC, the phase III Evaluating Treat-
ment with Neoadjuvant Abraxane (ETNA) trial has been
initiated. (Table 3) [29, 50]. Sequential neoadjuvant nab-
paclitaxel and EC are also being evaluated in early-stage
breast cancer in a phase II trial [51]. Based on the efficacy
of carboplatin with nab-paclitaxel, particularly in TNBC,
an ongoing phase II study is examining this combination in
LABC or inflammatory TNBC [30, 34, 36, 41, 52, 53].
Neoadjuvant nab-paclitaxel will also be tested with car-
boplatin, AC, and bevacizumab with pegfilgrastim support
for locally invasive TNBC [54]. nab-Paclitaxel plus car-
boplatin will be combined with trastuzumab for early
HER2? disease or with bevacizumab for HER2- cancers
[55]. In addition, based on data showing increased
expression of epidermal growth factor receptor (EGFR) in
half of inflammatory breast cancers, the EGFR monoclonal
antibody panitumumab will be combined with carboplatin,
FEC, and nab-paclitaxel for HER2- IBC [56, 57]. The
results of these ongoing neoadjuvant nab-paclitaxel-based
trials may yield improved treatment options for patients
with breast cancer.
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Future directions: nab-paclitaxel and immune
therapy
Upon exposure to chemotherapeutic agents, dying tumor
cells induce immune responses and promote the release of
tumor antigens [58, 59]. Preclinical data suggest syner-
gistic activity between chemotherapy and checkpoint
inhibitors [60]. In mouse models of pancreatic cancer
resistant to immune checkpoint inhibition alone, addition
of nab-paclitaxel to immune checkpoint inhibitors
improved response and survival [61]. nab-Paclitaxel also
demonstrated clinical benefit when combined with check-
point inhibitors in multiple types of solid tumors. A phase
Ib study of atezolizumab, a PD-L1 inhibitor, combined
with nab-paclitaxel demonstrated activity in 5 evaluable
patients with metastatic TNBC (4 partial responses, 1
stable disease) and tolerability [62]. First-line treatment of
locally advanced or metastatic non-small cell lung cancer
(N = 58) with atezolizumab plus nab-paclitaxel and car-
boplatin resulted in 25 % complete response and 31.25 %
partial response rate, with an ORR of 56 % (95 % CI
30–80 %) [63]. Atezolizumab in combination with nab-
paclitaxel vs placebo plus nab-paclitaxel as first-line
treatment for metastatic TNBC is currently being evaluated
in the phase III IMpassion130 trial (planned N = 350;
NCT02425891) [64]. The combination of atezolizumab
and nab-paclitaxel is also being evaluated as a neoadjuvant
regimen in an ongoing phase II trial in early-stage TNBC
[65]. Similarly, the combination of the PD-L1 inhibitor
durvalumab plus nab-paclitaxel is being examined as
neoadjuvant therapy for early-stage TNBC in an ongoing
phase I/II trial [66]. An ongoing trial will also examine
nivolumab, a PD-1 inhibitor, in combination with nab-pa-
clitaxel for recurrent, HER2- MBC [67]. Results from
these trials may provide further rationale for combining
nab-paclitaxel with immune therapies as an exciting new
treatment approach for early-stage breast cancer.
Conclusions
In summary, nab-paclitaxel appears to be an effective and
well-tolerated neoadjuvant therapy for breast cancer.
Ongoing and future trials will further evaluate nab-pacli-
taxel in all subtypes of breast cancer, including TNBC,
which exhibits a particularly high sensitivity to this treat-
ment strategy. Future studies should examine the long-term
benefits of nab-paclitaxel vs paclitaxel and should explore
combining nab-paclitaxel with novel immunological ther-
apies. The inclusion of molecular or biological/immuno-
logical analyses in future trials should help identify
predictive markers of response, which can be used to guide
patient selection and ultimately improve response rates to
neoadjuvant nab-paclitaxel-based regimens.
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